Abstract:Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group ( n = 120), sitagliptin group ( n = 120), and control group ( n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant ( p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups ( p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN. Clinical Trial Registration: (https://www.chictr.org.cn/index.aspx), identifier (ChiCTR2200056148).

S517 The Effect of GLP-1 Receptor Agonists on Bowel Preparation

S349 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis

Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy

S862 Impact of GLP-1 Receptor Agonist Indication on Gastric Retention and Boston Bowel Preparatory Score

S309 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Patients Undergoing Colonoscopy

Effect of Small Bowel Preparation with Simethicone on Capsule Endoscopy.

S522 African American Patients Taking GLP-1RA are More Likely to Have Poor Bowel Prep: A Single Center Study

Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists

S541 Glucagon-Like Peptide-1 Receptor Agonist Use and its Potential Impact in Colonoscopy Among Patients Undergoing Colorectal Cancer Screening: A Multicenter Propensity Score Matching Analysis

S919 Debunking Endoscopy Myths: GLP1-RA Use and GI Symptoms Do NOT Predict Bowel Preparation Success

S920 Clear Liquid Diet and Colonoscopy Bowel Preparation Are Effective in Eliminating Retained Gastric Contents in Those on GLP1-RA Agents Undergoing Endoscopic Procedures

Improved Capsule Endoscopy after Bowel Preparation.

Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates On Upper Endoscopy Especially In Complicated Diabetic Patients: A Case Control Study

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gastric Mucosal Visibility and Retained Gastric Contents During Esophagogastroduodenoscopy.

Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy

Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy in Diabetic and Non-Diabetic Patients

S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network

Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists

Exploration of an Improved Bowel Preparation for Inflammatory Bowel Disease Patients